JPRN-UMIN000021884已完成未知
Clinical Research of Diquas ophthalmic solution 3% on corneal epithelial barrier function in dry eye - Clinical Research of Corneal epithelial barrier function
Collaborative joint clinical research organized with Kyorin university School of Medicine and Santen Pharmaceutical Co., Ltd.0 个研究点目标入组 20 人开始时间: 2016年4月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with a history of allergy to fluorescein Patients who have allergic conjunctivitis, and have possibilities to get worse during study phase. Experience in using Diquas ophthalmic solution 3%. The investigator or subinvestigator has judged that the patient is ineligible as study subject.
研究者
相似试验
已完成
不适用
The efficacy of DIQUAS ophthalmic solution 3% for dry eye patients before cataract surgeryDry eyeJPRN-UMIN000029333Santen Pharmaceutical Co., Ltd.69
已完成
2 期
Safety and Efficacy of an Ophthalmic Solution in Dry Eye DiseaseDry Eye DiseaseNCT00758784Bausch & Lomb Incorporated38
已完成
不适用
Safety and efficacy of 3% diquafosol ophthalmic solution for soft contact lens-related dry eye.Dry eyeJPRN-UMIN000024064Santen Pharmaceutical Co., Ltd.26
已完成
不适用
Clinical effects of 3% diquafosol ophthalmic solution in dry eye disease patients using VDTDry EyeJPRN-UMIN000008990Tokyo Electric Power hospital100
已完成
不适用
Cross-linked CMC and Silk Proteins in Eye DiseaseDry Eye Disease (DED)NCT06605365D&V FARMA srl20